AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05373446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSD8432 750mg
Description: SSD8432 750mg in combination with ritonavir 100mg, day1--day5,BID
Study NCT05373446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SSD8432Placebo
Description: SSD8432Placebo in combination with ritonavir placebo,day1--day5,BID
Study NCT05011227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 2 cycles Camrelizumab before endoscopic surgery and one year after
Study NCT05011227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: 2 cycles Gemcitabine based chemotherapy before endoscopic surgery, with or without after surgery
Study NCT05011227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic surgery
Description: standard endoscopic surgery for recurrent nasopharyngeal carcinoma
Study NCT06355427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-FAPI PET-CT
Description: \[18F\]F-FAPI PET-CT in addition to regular CT and MRI, prior to participants undergoing surgery
Study NCT06008327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical 15% Trichloroacetic acid
Description: Recently trichloroacetic acid (TCA), a superficial chemical exfoliative agent has shown efficacy in treating acanthosis nigricans. Data from this would help in establishing it as a treatment of choice thereby lead to reduction in cost and benefit the patient both financially and psychologically.
Study NCT05513352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS - transcranial alternating current stimulation
Description: TACS is a non-invasive brain stimulation (NIBS) techniques that belong to the class of low current transcranial electric stimulation. In contrast to the better known transcranial direct current stimulation (tDCS), the tACS current is not constant, but alternates with a certain frequency.~The stimulation will be applied over the left temporo-parietal cortex at participants' individual alpha frequency. The stimulation intensity will be 2 milliampere (mA, peak-to-peak value, corresponding to a sine wave of ±1 mA amplitude). Stimulation will be delivered through conductive rubber electrodes.
Study NCT05513352 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham - transcranial alternating current stimulation
Description: During sham stimulation (placebo), tACS will be ramped up and down for 12 seconds , that is, no electric stimulation wil be applied during the actual experiment. The up and down ramping will be repeated at the end of the experiment.~The sham condition serves to evoke sensations associated with tACS stimulation, but without stimulating during the actual experiment.
Study NCT05277220 — intervention group
Intervention type: DEVICE
Intervention: Thermal Camera Thermo Malin TC
Description: Thermo Malin TC thermal camera (also called HIKVISION TP 31B portable thermal camera). Manufacturer of the researched product is HIKVISION.~This thermal camera is equipped with a thermal detector with a resolution of 160 x 120 elements or an infrared resolution of 19,200 pixels.~Thermal sensitivity of the Thermo Malin TC thermal imager is 40 milliKelvin (0.04 °C), with a spatial resolution of 5.48 mrad and a field of view of 37.2 x 50 °. Temperature accuracy at one point varies by +/- 0.5 °C. This thermal imager has four color palettes to highlight the desired elements.~This camera is specially designed for measuring body temperature in a temperature range from +30 to + 45 °C.~As part of the research, the thermal camera will enable the acquisition and recording of thermographic images at three times of study. These images are then transferred to the operating software for the Thermo Malin Series to process, analyze and make changes to elements of thermographic images.
Study NCT06417580 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Treatment
Description: Desensitizing protocol with none active ingredient to evaluate the control of cervical dentin hypersensitivity
Study NCT06417580 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate Potassium Treatment
Description: Desensitizing protocol with potassium nitrate gel to analyze and compare with other groups the effects of controlling cervical dentin hypersensitivity
Study NCT06417580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pregabalin Treatment
Description: Desensitizing protocol with experimental 10% pregabalin gel to evaluate the control of cervical dentin hypersensitivity
Study NCT05213494 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Description: Inulin, a dietary fiber, will be given in a beverage daily in doses 3g, 5g, 6g, or 8g dependent on arm and age of participants.
Study NCT05213494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soluble corn fiber
Description: soluble corn fiber, a dietary fiber, will be given in a beverage daily in doses 3g, 5g, 6g, or 8g dependent on arm and age of participants.
Study NCT05322746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focal muscle vibration
Description: Focal muscle vibration (FMV) defined as a technique that applies a vibratory stimulus to a specific muscle or its tendon using a mechanical device. FMV generates the Ia inputs as a consequence of the activation primary ending of the muscle spindle leading to alteration of corticospinal pathways results in activation of Ia inputs by FMV. The vibration of a specific muscle can increase the motor evoked potential, enhance the changes in corticospinal excitability and produces involuntary contraction in the vibrated muscle
Study NCT05322746 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Focal muscle vibration
Description: Focal muscle vibration (FMV) defined as a technique that applies a vibratory stimulus to a specific muscle or its tendon using a mechanical device. FMV generates the Ia inputs as a consequence of the activation primary ending of the muscle spindle leading to alteration of corticospinal pathways results in activation of Ia inputs by FMV. The vibration of a specific muscle can increase the motor evoked potential, enhance the changes in corticospinal excitability and produces involuntary contraction in the vibrated muscle
Study NCT06097910 — intervention group
Intervention type: PROCEDURE
Intervention: Watchful waiting
Description: Conduct thoracic computed tomography scans every 12 months. If a solid component emerges of if there is an increase in the size of any lung nodules, the treamtent approach would involve surgery of radiotherapy.
Study NCT04251507 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus Go Virtual Reality Goggles
Description: Oculus Go is a standalone portable Virtual Reality device that enables the user to immerse in different virtual environments.Non pharmacological technique to reduce pain and anxiety during a procedure.
Study NCT05456802 — intervention group
Intervention type: OTHER
Intervention: Standard of care treatment
Description: Standard of care treatment including percutaneous interventions was performed in all participants.
Study NCT06578637 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: R-1,3-Butanediol (10MG-A)
Description: Study participants will take one 35mL dose of HVMN Ketone-IQ by mouth per day (10 total grams of R-1,3-Butanediol) for 2 weeks
Study NCT06578637 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: R-1,3-Butanediol (20MG-A)
Description: Study participants will take two 35mL dose of HVMN Ketone-IQ by mouth per day (20 total grams of R-1,3-Butanediol) for 2 weeks
Study NCT06578637 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: R-1,3-Butanediol (30MG-A)
Description: Study participants will take three 35mL dose of HVMN Ketone-IQ by mouth per day (30 total grams of R-1,3-Butanediol) for 2 weeks
Study NCT06578637 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: R-1,3-Butanediol (10MG-B)
Description: Study participants will take one 35mL dose of HVMN Ketone-IQ by mouth per day along with one 35mL dose of placebo ketone drink by mouth per day (10 total grams of R-1,3-Butanediol) for 12 weeks
Study NCT06578637 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: R-1,3-Butanediol (20MG-B)
Description: Study participants will take one 35mL dose of HVMN Ketone-IQ by mouth twice per day (20 total grams of R-1,3-Butanediol) for 12 weeks
Study NCT06578637 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will take one 35mL dose of placebo ketone drink by mouth twice daily for 12 weeks
Study NCT05188339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% sodium citrate
Description: Dose of 4% sodium citrate is also according to catheter lumen (LVR) instilled into each lumen of catheter after HD session, eg. 1.6 cc/lumen for LV R 1.6, 1.8 cc/lumen for LVR 1.8.~A prospective, open label, control study. The content of study protocol will be posted in the HD room in the Kaohsiung Chang Gung memorial Hospital, Taiwan. After inform consent obtained, we will categorize enrolled participants randomly into two groups, 4% sodium citrate group(experimental group), heparin group(control group), respectively. The study duration is three months.
Study NCT05188339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heparin group
Description: Heparin dosage is based on volume ratio in catheter lumen (LVR) after each HD session, eg. 8000u/lumen in 1.6 LVR, 9000u/lumen in LVR 1.8.
Study NCT04667182 — intervention group
Intervention type: OTHER
Intervention: Meal-Tagging App and Web-based Portal:
Description: Meal tagging app to capture frequently eaten meals and test meals for 18 weeks.
Study NCT04667182 — intervention group
Intervention type: DEVICE
Intervention: Fitness Tracker
Description: Fitness tracker will be worn around the clock for 18 weeks.
Study NCT05513352 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NF - Neurofeedback
Description: Neurofeedback (NF) is a non-invasive approach that combines neurophysiological recordings with real-time sensory feedback (most studies use visual feedback). Through real-time NF, individuals thus can learn to regulate their brain activity.~In this study, NF will be based on concurrent EEG recordings. During NF, participants will observe a space ship automatically navigating through a narrow tunnel. The modulation of their neural alpha power lateralization into the trained direction will be rewarded by the acceleration of the space ship, a modulation in the opposite direction will reduce speed and autopilot accuracy.
Study NCT05513352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NF - Neurofeedback
Description: Neurofeedback (NF) is a non-invasive approach that combines neurophysiological recordings with real-time sensory feedback (most studies use visual feedback). Through real-time NF, individuals thus can learn to regulate their brain activity.~In this study, NF will be based on concurrent EEG recordings. During NF, participants will observe a space ship automatically navigating through a narrow tunnel. The modulation of their neural alpha power lateralization into the trained direction will be rewarded by the acceleration of the space ship, a modulation in the opposite direction will reduce speed and autopilot accuracy.
Study NCT06256588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered as an intravenous (IV) infusion
Study NCT06256588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as an IV infusion
Study NCT01363700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-114 ophthalmic solution
Study NCT01363700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ophthalmic solution
Study NCT01363700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine Hydrochloride 0.1% Ophthalmic Solution
Study NCT06043752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remsima
Description: The patient will be given one Injection of REMSIMA 120 mg subcutaneously at week 0, 1, 2, 3, 4 and then every 2 weeks i.e., at 6, 8, 10 and 14 weeks. If the weight of the patient is >80 kg, 2 injections will be given.
Study NCT06443580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interoceptive group based intervention
Description: 8 week online group intervention aiming to improve interoception.
Study NCT04763421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENSEAL X1 Curved Jaw
Description: ENSEAL X1 Curved Jaw is used for vessel transection according to instructions for use.
Study NCT06041048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Single dose (200 mg) of medication versus placebo given to healthy control subjects
Study NCT06041048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modafinil
Description: Single dose (200 mg) of medication versus placebo given to healthy control subjects
Study NCT05520632 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Brainstem Auditory Evoked Potentials
Description: Performing Brainstem Auditory Evoked Potentials under sedation
Study NCT06606301 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BioSB EGFR antibody
Description: Appropriate sections from the tumor will be selected basing the choice on tumor content and viability eventually followed by EGFR application which will reveal a brown membrane positivity for the tumor. Total score for RGFR will be calculated by the histopathologists.
Study NCT06608290 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: parasternal block
Description: Administration of parasternal block with ropivacaine, bilaterally at the sternum before the start of surgery.
Study NCT06608290 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lactate serum level
Description: Blood samples were taken to identify serum lactate levels greater than 2 mmol/l and those that remained below this limit.
Study NCT06599606 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonographic Assessment
Description: A researcher will perform all ultrasonographic measurements using the ESAOTE My Lab 70 model ultrasound device with a 4-13 MHz linear probe. System settings will be kept constant throughout each study, and all images will be obtained using this single ultrasound device. Only the depth will be adjusted to optimally assess the relevant muscle. The muscle thickness measurement protocol with ultrasound includes four muscles on the dominant side of each child: two proximal upper and lower extremity muscles (biceps brachii/brachialis and quadriceps) and two distal upper and lower extremity muscles (forearm flexors and tibialis anterior). In the assessment of muscle echogenicity, images will be transferred to ImageJ software to calculate luminance ratios (LR).
Study NCT01473290 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: live freeze-dried lactic acid bacteria probiotic
Description: Given orally (PO)
Study NCT01473290 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT05289063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10mg
Description: Atorvastatin 10 mg daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
Study NCT05289063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
Study NCT05289063 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Positive Airway Pressure Therapy
Description: CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP.
Study NCT05289063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure Therapy
Description: CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP.
Study NCT05845086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative patient education
Description: In this study, preoperative patient education will be given, reinforced with multimedia supported written and verbal teach-back method, created according to the literature. Videos of exercises used to increase postoperative mobilization (deep breathing exercise, coughing exercise, intensive spirometer use, etc.) will be taken by the researcher in a professional studio. The captured videos will be embedded in the PowerPoint presentation and presented to the patient with a tablet computer. The powerpoit presentation should be a maximum of 30 slides and the patient education should take a maximum of 30 minutes. Patients will be evaluated face-to-face on the 1st, 2nd, 3rd days after surgery and by phone on the 15th day. The prepared powerpoint presentation will be left with the patient as a printout. The prepared video will be given to the patient after the training with a program (via WhatsApp, e-mail, bluetooh) on their phones in accordance with the preferences of the patients.
Study NCT06610955 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity interval training
Description: After a 10 minutes warm up exercise, participants will exercise with a bicycle ergometry device at 80% of their maximum heart rate for 4 minutes, and the active recovery period will be 3 minutes (4x4 minutes). During the recovery period, the participant will exercise with the Ergoline bicycle ergometry system for 4 sets at 60% of their maximum heart rate for 3 minutes. A total of 45 minutes exercise session will be completed with a 10 minutes cool down exercise. Exercise will be done 5 days a week for a total of 8 weeks. In the first 4 weeks, exercise will be done at 80% intensity, and in the following weeks, the exercise intensity will be increased by 5% each week, respectively, to 85%, 90%, 95%, and 100% in the last week.
Study NCT06610955 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity continuous training
Description: Following a 10 minutes warm up exercise, participants will exercise continuously for 30 minutes at 65% of their maximum heart rate with the Ergoline bicycle ergometry system. A 5 minutes cool down exercise will end the 45 minutes exercise session. The exercise duration is 5 days a week for a total of 8 weeks.
Study NCT04982939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab, 200mg IV d1 Q3W
Study NCT04982939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: S-1, 40-60mg BID d1-14 Q3W
Study NCT04982939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1, 40-60mg BID d1-14 Q3W
Study NCT04982939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin，130mg/m2 d1 Q3W
Study NCT04982939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin，130mg/m2 d1 Q3W
Study NCT05014672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setanaxib
Description: Oral tablets, 400mg per tablet
Study NCT05014672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study NCT04977284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DS7R, Digitimer, UK
Description: Non-surgical spinal cord stimulation will be applied and electrical activity of muscles will be recorded.
Study NCT04932928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre
Description: Flash glucose monitoring + Education on lifestyle modification
Study NCT04932928 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood glucose meter
Description: Self monitoring of blood glucose + Education on lifestyle modification
Study NCT06610734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab combined with chemotherapy synchronous LDRT
Study NCT05642585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: Single oral
Study NCT06610734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adebrelimab
Description: Adebrelimab combined with chemotherapy synchronous LDRT
Study NCT06610734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy
Study NCT06610734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy
Study NCT06610734 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low dose radiotherapy
Description: low dose radiotherapy
Study NCT06610188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic group
Description: products containing a total of 9.2 g (4.6 g twice a day) inulin/oligofructose (50/50) mixture (prebiotic group) that individuals should consume daily were delivered to individuals in identical opaque bags.
Study NCT06610188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin (Placebo)
Description: products containing a total of 9.2 g (4.6 g twice a day) maltodextrin (placebo group) that individuals should consume daily were delivered to individuals in identical opaque bags.